<code id='2D73F7B9AD'></code><style id='2D73F7B9AD'></style>
    • <acronym id='2D73F7B9AD'></acronym>
      <center id='2D73F7B9AD'><center id='2D73F7B9AD'><tfoot id='2D73F7B9AD'></tfoot></center><abbr id='2D73F7B9AD'><dir id='2D73F7B9AD'><tfoot id='2D73F7B9AD'></tfoot><noframes id='2D73F7B9AD'>

    • <optgroup id='2D73F7B9AD'><strike id='2D73F7B9AD'><sup id='2D73F7B9AD'></sup></strike><code id='2D73F7B9AD'></code></optgroup>
        1. <b id='2D73F7B9AD'><label id='2D73F7B9AD'><select id='2D73F7B9AD'><dt id='2D73F7B9AD'><span id='2D73F7B9AD'></span></dt></select></label></b><u id='2D73F7B9AD'></u>
          <i id='2D73F7B9AD'><strike id='2D73F7B9AD'><tt id='2D73F7B9AD'><pre id='2D73F7B9AD'></pre></tt></strike></i>

          entertainment

          entertainment

          author:knowledge    Page View:139
          Sammy Kimball for STAT

          Can biotech startups survive a downturn? Is Covid-19 a good business? And when did ophthalmology get so dramatic?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss what some recent layoffs and a reverse merger mean for biotech in 2023. We’ll also discuss the latest news in the life sciences, including a dramatic saga in ocular medicine, the volatile business of Covid-19, and some major milestones in gene therapy.

          advertisement

          For more on what we cover, here’s the news on Celsius Therapeutics; here’s more on EQRx; here’s the latest on Apellis Pharmaceuticals; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          explore

          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more
          The Biogen Aduhelm mess could happen again
          The Biogen Aduhelm mess could happen again

          BiogenrecentlyannounceditwillceaseboththestudyandsaleofitsAlzheimer'sdrugAduhelm.JessicaRinaldi/TheB

          read more
          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more

          Medicare Advantage plans can’t deny care with AI, CMS warns

          AdobeInrecentmonths,thefederalgovernmenthasrepeatedlytoldMedicareAdvantageinsurersthattheycannotusea